{"id":1520,"text":"Edited by: Emilio Clementi, University of Milano, Italy Reviewed by: Paavo Honkakoski, University of Eastern Finland, Finland; Oliver Burk, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Germany; Paul Cos, Antwerp University, Belgium This article was submitted to Pharmaceutical Medicine and Outcomes Research, a section of the journal Frontiers in Pharmacology.","label":[],"Comments":[]}
{"id":1521,"text":"Labisia pumila (Kacip Fatimah) is a popular herb in Malaysia that has been traditionally used in a number of women’s health applications such as to improve libido, relieve postmenopausal symptoms, and to facilitate or hasten delivery in childbirth.","label":[[0,30,"Herb name"],[109,114,"Sex"],[156,162,"Parameter"],[172,195,"Pathology"]],"Comments":[]}
{"id":1522,"text":"In addition, the constituents of this plant have been reported to possess anticancer, antioxidant, and anti-inflammatory properties.","label":[[13,43,"Herb name"],[74,84,"Pathology"],[103,120,"Pathology"]],"Comments":[]}
{"id":1523,"text":"Clinical studies have indicated that cytochrome P450s (CYPs), P-glycoprotein (P-gp), and Pregnane X receptor (PXR) are the three main modulators of drug-drug interactions which alter the absorption, distribution, and metabolism of drugs.","label":[[0,16,"Study"],[37,60,"Parameter"],[62,83,"Parameter"],[89,114,"Parameter"],[187,236,"Parameter"]],"Comments":[]}
{"id":1524,"text":"Given the widespread use of Kacip Fatimah in dietary supplements, the current study focuses on determining the potential of its constituents to affect the activities of CYPs, P-gp, or PXR using in vitro assays which may provide useful information toward the risk of herb-drug interaction with concomitantly used drugs.","label":[[28,41,"Herb name"],[151,187,"Parameter"],[194,209,"Study"]],"Comments":[]}
{"id":1525,"text":"Six compounds isolated from the roots of L. pumila (2 saponins and 4 alkyl phenols) were tested, in addition to the methanolic extract.","label":[[28,37,"Herb part"],[41,82,"Herb name"],[112,134,"Extraction process"]],"Comments":[]}
{"id":1526,"text":"The extract of L. pumila showed a significant time dependent inhibition (TDI) of CYP3A4, reversible inhibition of CYP2C9 and 2C19 and a weak inhibition of 1A2 and 2D6 as well as an inhibition of P-gp and rifampicin-induced PXR activation.","label":[[0,24,"Herb name"],[81,87,"Target"],[114,120,"Target"],[125,129,"Target"],[155,158,"Target"],[163,166,"Target"],[195,199,"Target"],[204,214,"Drug"],[204,237,"Parameter"],[223,226,"Target"]],"Comments":[]}
{"id":1527,"text":"The alkyl phenols inhibited CYP3A4 (TDI), CYP2C9, and 2C19 (reversible) while saponins inhibited P-gp and PXR.","label":[[0,17,"Herb name"],[28,58,"Target"],[78,86,"Herb name"],[97,109,"Target"]],"Comments":[]}
{"id":1528,"text":"In conclusion, L. pumila and its constituents showed significant modulation of all three regulatory proteins (CYPs, P-gp, and PXR) suggesting a potential to alter the pharmacokinetic and pharmacodynamic properties of conventional drugs if used concomitantly.","label":[[15,45,"Herb name"],[110,129,"Target"]],"Comments":[]}
{"id":1529,"text":"Labisia pumila (Blume) Fern.-Vill., locally termed as Kacip Fatimah (KF), is a popular herb in South East Asian countries.","label":[[0,34,"Herb name"],[54,72,"Herb name"],[95,111,"Ethnic group"]],"Comments":[]}
{"id":1530,"text":"It belongs to the Myrsinaceae family.","label":[[14,36,"Herb name"]],"Comments":[]}
{"id":1531,"text":"Recently it has been identified as one of the top five herbs used in Malaysia for treating variety of ailments (Karimi et al., 2013).","label":[[102,110,"Pathology"]],"Comments":[]}
{"id":1532,"text":"Traditionally, KF is mainly used in a wide spectrum of women’s health related issues; the effects are presumed as attributable to the presence of estrogen-like compounds.","label":[[15,17,"Herb name"],[55,60,"Sex"],[146,169,"Herb name"]],"Comments":[]}
{"id":1533,"text":"KF is often taken during and after pregnancy for its beneficial effects on uterine function and delivery.","label":[[0,2,"Herb name"],[35,44,"Parameter"],[75,104,"Parameter"]],"Comments":[]}
{"id":1534,"text":"The primary route of administration of KF is oral, whereby the leaves, roots, or whole plant are boiled in water and consumed.","label":[[39,41,"Herb name"],[59,76,"Herb part"],[97,112,"Extraction process"]],"Comments":[]}
{"id":1535,"text":"Additionally, it is sold commercially in the form of herbal tea, powder, capsules, and tablets in many countries (Abdul Kadir et al., 2012).","label":[[53,94,"Extraction process"]],"Comments":[]}
{"id":1536,"text":"Clinical studies have also suggested the usefulness of KF extract in treating postmenopausal symptoms (Abdul Kadir et al., 2012) with no acute toxicity (Singh et al., 2009).","label":[[0,16,"Study"],[55,65,"Herb name"],[78,101,"Pathology"],[137,151,"Pathology"]],"Comments":[]}
{"id":1537,"text":"Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).","label":[[13,47,"Herb name"],[75,151,"Pathology"]],"Comments":[]}
{"id":1538,"text":"Due to the increasing popularity and wide spread use of herbal supplements throughout the world, there is a potential risk of herb-drug interactions when these supplements are taken in combination with conventional drugs, as there is often limited standardization of dose of herbal supplements taken.","label":[[56,74,"Herb name"],[202,220,"Drug"]],"Comments":[]}
{"id":1539,"text":"This is evident by the increasing reports of clinical cases of toxicity caused by herb-drug interactions (Chen et al., 2011, 2012).","label":[[34,59,"Study"],[63,71,"Pathology"]],"Comments":[]}
{"id":1540,"text":"Early identification of drug interaction potential of herbal supplements and their constituents will aid in lowering the risk of herb-drug interactions.","label":[],"Comments":[]}
{"id":1541,"text":"It is widely documented that CYPs, P-gp, and PXR are the three main modulators of drug-drug interactions as these are involved in affecting the pharmacokinetic and pharmacodynamic properties of xenobiotics (Alissa, 2014).","label":[[29,48,"Parameter"],[194,205,"Drug"]],"Comments":[]}
{"id":1542,"text":"Despite the use of KF as a herbal medicine, limited studies exist in literature for its drug interaction potential.","label":[[19,42,"Herb name"]],"Comments":[]}
{"id":1543,"text":"A recent study has indicated that different extracts of L. pumila show potent inhibition of CYPs, specifically CYP2C isoforms (Pan et al., 2012).","label":[[44,65,"Herb name"],[92,125,"Target"]],"Comments":[]}
{"id":1544,"text":"However, there are no studies identifying the chemical constituents of KF responsible for CYP inhibition.","label":[[71,73,"Herb name"],[90,93,"Target"]],"Comments":[]}
{"id":1545,"text":"As part of our phytochemical studies on medicinal plants, several constituents have been isolated from the roots of L. pumila; these belong to various chemical classes, including saponins, alkyl phenols, cerebroside, glycerogalactolipids, and lipids (Ali and Khan, 2011).","label":[[15,56,"Study"],[103,112,"Herb part"],[116,125,"Herb name"],[179,249,"Herb name"]],"Comments":[]}
{"id":1546,"text":"In the extension of these studies, the current investigation focuses on determining the potential of KF methanolic extract and its constituents to affect the activities of major drug metabolizing enzymes (CYP 3A4, 2D6, 1A2, 2C9, and 2C19), P-gp, and PXR using in vitro assays which may provide useful information toward the risk of herb-drug interactions with concomitantly used drugs.","label":[[101,103,"Herb name"],[104,122,"Extraction process"],[178,253,"Parameter"],[260,275,"Study"]],"Comments":[]}
{"id":1547,"text":"The inhibition of CYP 3A4, 2D6, 1A2, 2C9, and 2C19 was determined by employing C-DNA baculovirus expressed recombinant enzymes and specific fluorescent substrates.","label":[[18,50,"Target"],[79,126,"Parameter"]],"Comments":[]}
{"id":1548,"text":"The inhibition of P-gp was determined in hMDR1-MDCK-II (Madin-Darby canine kidney) and MDCK-II cells by using two widely used substrates calcein-AM and digoxin.","label":[[18,22,"Target"],[137,147,"Herb name"],[152,159,"Drug"]],"Comments":[]}
{"id":1549,"text":"Modulation of PXR activity was monitored through a reporter gene assay in HepG2 cells transfected with PXR plasmid DNA and a luciferase reporter plasmid PCR5.","label":[[14,26,"Parameter"],[103,118,"Parameter"]],"Comments":[]}
{"id":1550,"text":"Additionally, we used FDA guided assumptions (Zhang et al., 2009) to predict the likelihood of the KF extract and its constituents to cause herb drug interactions (HDI) in vivo.","label":[[99,109,"Herb name"]],"Comments":[]}
{"id":1551,"text":"Madin-Darby canine kidney-II (parental) and hMDR1-MDCK-II (transfected) cell lines were a gift from Dr. Gottesman (NIH, Bethesda, USA).","label":[],"Comments":[]}
{"id":1552,"text":"Dulbecco’s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).","label":[[73,108,"Extraction process"],[110,115,"Extraction process"],[117,129,"Extraction process"],[131,154,"Drug"],[160,175,"Extraction process"]],"Comments":[]}
{"id":1553,"text":"Fetal bovine serum (FBS) was from Hyclone Lab Inc. (Logan, UT, USA).","label":[[0,24,"Extraction process"]],"Comments":[]}
{"id":1554,"text":"CYP1A2\/CEC, CYP2C9\/MFC, CYP3A4\/BQ, CYP2C19\/CEC, and CYP2D6\/AMMC high throughput inhibitor screening kits were from BD Gentest (Woburn, MA, USA).","label":[[0,63,"Parameter"]],"Comments":[]}
{"id":1555,"text":"Transwell plates (12 mm diameter, 0.4 μM pore size) were from Costar Corp. (Cambridge, MA, USA).","label":[],"Comments":[]}
{"id":1556,"text":"All other chemicals were from Sigma Chem.","label":[],"Comments":[]}
{"id":1557,"text":"Co., (St. Louis, MO, USA).","label":[],"Comments":[]}
{"id":1558,"text":"Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 μL in 96-well microplates.","label":[[14,21,"Drug"],[100,103,"Amount"],[104,107,"Extraction process"],[109,111,"Amount"],[112,137,"Herb name"],[139,141,"Amount"],[214,220,"Amount"]],"Comments":[]}
{"id":1559,"text":"The assay conditions, enzyme and substrate concentrations were similar as reported earlier (Crespi et al., 1997; Manda et al., 2013).","label":[[22,57,"Parameter"]],"Comments":[]}
{"id":1560,"text":"Test samples or positive controls were serially diluted in a solution (100 μL) of cofactors mix, control protein (0.05 mg of protein\/mL), and G-6-PDH to achieve six concentrations (100-0.4 μM or μg\/mL).","label":[[71,77,"Amount"],[82,95,"Parameter"],[97,112,"Parameter"],[114,135,"Amount"],[142,149,"Parameter"],[165,179,"Parameter"],[181,200,"Amount"]],"Comments":[]}
{"id":1561,"text":"Initial readings were taken to record any inherent fluorescence and the plates were incubated at 37°C for 10 min.","label":[[97,99,"Amount"],[99,101,"Parameter"],[102,112,"Duration"]],"Comments":[]}
{"id":1562,"text":"Reaction was initiated by the addition of enzyme substrate mixture (100 μL) followed by incubation for 15, 30, or 45 min.","label":[[42,66,"Parameter"],[68,74,"Amount"],[99,120,"Duration"]],"Comments":[]}
{"id":1563,"text":"The reaction was terminated by the addition of 75 μL of ice cold acetonitrile\/0.5 M Tris base (80:20).","label":[[47,52,"Amount"],[56,101,"Extraction process"],[78,83,"Amount"]],"Comments":[]}
{"id":1564,"text":"Fluorescence was measured on Spectramax M5 plate reader (Molecular Devices, Sunnyvale, CA, USA) at specified excitation and emission wavelengths for each substrate.","label":[[0,12,"Parameter"]],"Comments":[]}
{"id":1565,"text":"IC Time dependent inhibition (TDI) of CYPs was measured as described earlier by Sekiguchi et al.","label":[[3,42,"Parameter"]],"Comments":[]}
{"id":1566,"text":"(2009).","label":[],"Comments":[]}
{"id":1567,"text":"The reaction mixture (180–190 μL), consisting of test sample, recombinant enzyme, control protein (0.05 mg of protein\/mL), cofactor mix, G-6-PDH, and 50 mM potassium phosphate buffer (pH 7.4) was pre-incubated for 30 min followed by addition of respective fluorescent substrates (10–20 μL) and further incubation for 15 (CYP1A2), 30 (CYP3A4), or 45 (CYP 2C9 and 2C19) min.","label":[[22,32,"Amount"],[62,80,"Parameter"],[82,97,"Parameter"],[99,120,"Amount"],[123,135,"Parameter"],[137,144,"Parameter"],[150,155,"Amount"],[156,182,"Extraction process"],[184,186,"Parameter"],[187,190,"Amount"],[210,220,"Duration"],[256,278,"Parameter"],[280,288,"Amount"],[317,319,"Duration"],[321,327,"Parameter"],[330,332,"Duration"],[334,340,"Parameter"],[346,371,"Duration"],[350,366,"Parameter"]],"Comments":[]}
{"id":1568,"text":"The reaction was terminated by addition of 75 μL of ice cold acetonitrile\/0.5 M Tris base (80:20) and fluorescence was measured as above.","label":[[43,48,"Amount"],[52,97,"Extraction process"],[74,79,"Amount"],[102,114,"Parameter"]],"Comments":[]}
{"id":1569,"text":"IC The pSG5-hPXR expression vector was provided generously by Dr. Steven Kliewer (University of Texas Southwestern Medical Center, Dallas, TX, USA; Lehmann et al., 1998) and the reporter plasmid CYP3A4-PXR response element (PXRE)-LUC (containing the proximal 0\/–362 and distal 7208\/7797 PXRE regions fused upstream of luciferase; Goodwin et al., 1999) was a kind gift from Dr. Christopher Liddle (University of Sydney, Westmead, NSW, Australia).","label":[[3,34,"Parameter"],[174,234,"Parameter"]],"Comments":[]}
{"id":1570,"text":"The modulation of PXR activity by test samples was determined in HepG2 cells transiently transfected with pSG5-PXR (25 μg) and PCR5 plasmid DNA (25 μg) by electroporation at 180 V, 1 pulse for 70 msec.","label":[[18,30,"Parameter"],[106,114,"Parameter"],[116,121,"Amount"],[127,143,"Parameter"],[145,150,"Amount"],[181,182,"Amount"],[183,188,"Parameter"],[193,200,"Duration"]],"Comments":[]}
{"id":1571,"text":"The cells were plated in 96-well plates at a density of 50,000 cells per well.","label":[],"Comments":[]}
{"id":1572,"text":"After 24 h, test samples and drug controls were added at various concentrations.","label":[[0,10,"Duration"],[65,79,"Parameter"]],"Comments":[]}
{"id":1573,"text":"After additional 24 hour incubation, the media was aspirated and 40 μL of luciferase reagent (Promega Corporation, Madison, WI, USA) was added to each well and luminescence was measured on Spectramax M5 plate reader (Molecular Devices, Sunnyvale, CA, USA).","label":[[17,24,"Duration"],[65,70,"Amount"],[74,92,"Extraction process"]],"Comments":[]}
{"id":1574,"text":"The fold induction in luciferase activity in the treated cells was calculated in comparison to vehicle treated cells.","label":[[22,41,"Parameter"]],"Comments":[]}
{"id":1575,"text":"The cytotoxicity of test samples toward HepG2 cells was also determined by measuring the cell viability using the CellTiter 96 AQ The assay was performed as described previously (Rautio et al., 2006).","label":[[4,16,"Pathology"],[89,103,"Parameter"]],"Comments":[]}
{"id":1576,"text":"Cells were seeded in 96-well plates at 70,000 cells\/well in 200 μL of culture medium.","label":[],"Comments":[]}
{"id":1577,"text":"The medium was changed at 24 h after seeding and the assay was performed 48 h later.","label":[[26,30,"Duration"],[73,83,"Duration"]],"Comments":[]}
{"id":1578,"text":"Test samples at various concentrations and positive control (verapamil 100-0.4 μM) were added to the cells in 50 μL of transport buffer and incubated at 37°C for 10 min.","label":[[24,38,"Parameter"],[61,70,"Drug"],[71,81,"Amount"],[110,115,"Amount"],[119,135,"Extraction process"],[153,155,"Amount"],[155,157,"Parameter"],[158,168,"Parameter"]],"Comments":[]}
{"id":1579,"text":"Calcein-AM (1 μM), a fluorescent P-gp substrate) was added and the plates were immediately placed on Spectramax and fluorescence was read up to 1 h at 15-min intervals at excitation and emission wavelengths of 485 and 530 nm, respectively.","label":[[0,47,"Herb name"],[12,16,"Amount"],[33,37,"Parameter"],[116,128,"Parameter"],[144,147,"Duration"],[151,157,"Duration"],[171,206,"Parameter"],[210,224,"Amount"]],"Comments":[]}
{"id":1580,"text":"The % increase in calcein-AM uptake was calculated as described earlier (Liu et al., 2008; Manda et al., 2014).","label":[[18,28,"Herb name"],[18,35,"Parameter"]],"Comments":[]}
{"id":1581,"text":"The EC The assay conditions were similar as described earlier (Rautio et al., 2006) with some modifications.","label":[],"Comments":[]}
{"id":1582,"text":"The cells were seeded at a density of 120,000 cells\/well in 12-well Transwell plates and cultured for 3 days.","label":[[102,108,"Duration"]],"Comments":[]}
{"id":1583,"text":"TEER values were in the range of 500–800 Ω cm The inhibition of the basolateral to apical (B-A) transport of digoxin by test samples was calculated compared to the vehicle control.","label":[[96,116,"Parameter"],[109,116,"Drug"]],"Comments":[]}
{"id":1584,"text":"The IC All assumptions to predict the HDI potential of KF methanolic extract and its constituents were according to previously published report (Awortwe et al., 2014).","label":[[55,57,"Herb name"],[58,76,"Extraction process"]],"Comments":[]}
{"id":1585,"text":"The % yield was calculated from the amounts extracted from the KF roots (Ali and Khan, 2011).","label":[[63,65,"Herb name"],[66,71,"Herb part"]],"Comments":[]}
{"id":1586,"text":"The human GIT volume is 250 mL and plasma volume is about 3 L. The commonly used maximum dose of KF extract capsules is 560 mg per day (Abdul Kadir et al., 2012) and accordingly we estimated the concentration per dose, GIT, and plasma concentrations of extract and its constituents.","label":[[0,20,"Parameter"],[24,30,"Amount"],[35,48,"Parameter"],[58,61,"Amount"],[97,99,"Herb name"],[100,116,"Extraction process"],[120,126,"Amount"],[120,134,"Frequency"],[191,217,"Parameter"],[219,222,"Parameter"],[228,281,"Parameter"]],"Comments":[]}
{"id":1587,"text":"We then compared the in vitro IC All values are represented as mean ± SD (n = 3).","label":[],"Comments":[]}
{"id":1588,"text":"The data were analyzed by one way ANOVA, followed by Dunnett’s multiple comparison tests using GraphPad Prism Version 5, (San Diego, CA, USA).","label":[],"Comments":[]}
{"id":1589,"text":"P < 0.05 was considered to be statistically significant.","label":[],"Comments":[]}
{"id":1590,"text":"The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011).","label":[[49,58,"Herb part"],[62,64,"Herb name"],[69,119,"Herb name"]],"Comments":[]}
{"id":1591,"text":"We have determined the effect of methanolic extract of KF and its six constituents (4 alkyl phenols and 2 saponins, Figure 1 on major CYPs using specific fluorescent substrates and recombinant enzymes.","label":[[33,51,"Extraction process"],[55,57,"Herb name"],[84,114,"Herb name"],[134,138,"Parameter"],[154,200,"Parameter"]],"Comments":[]}
{"id":1592,"text":"Chemical structures of two saponins and four alkyl phenols isolated from the roots of Labisia pumila.","label":[[23,58,"Herb name"],[73,82,"Herb part"],[86,100,"Herb name"]],"Comments":[]}
{"id":1593,"text":"The methanolic extract and alkyl phenolic compounds showed dose dependent inhibition of CYP3A4, 2C9, and 2C19 (Figures 2–4) while saponins did not affect the activity of these enzymes.","label":[[0,22,"Extraction process"],[27,51,"Herb name"],[88,109,"Target"],[130,138,"Herb name"],[154,183,"Parameter"]],"Comments":[]}
{"id":1594,"text":"Out of the alky phenols, 5-[10(Z)-pentadecenyl]-resorcinol was effective in inhibiting CYP3A4 and 2C9 with IC Dose response profiles of reversible and time dependent inhibition (TDI) of CYP3A4 enzyme by Labisia pumila root extract (A) and its alkyl phenolic constituents (B–E).","label":[[7,23,"Herb name"],[25,58,"Herb name"],[87,101,"Target"],[136,199,"Parameter"],[203,230,"Herb name"],[218,222,"Herb part"],[243,270,"Herb name"]],"Comments":[]}
{"id":1595,"text":"The data are represented as mean ± SD of 3 independent experiments (n = 2 in each experiment).","label":[],"Comments":[]}
{"id":1596,"text":"Based on these results, we further tested the TDI potential of extract and selected constituents toward CYP3A4, 2C9, and 2C19.","label":[[42,70,"Parameter"],[63,70,"Herb name"],[104,125,"Parameter"]],"Comments":[]}
{"id":1597,"text":"The test samples were pre-incubated for 30 min with the co-factors, control protein, and specific enzymes before substrates were added.","label":[[40,46,"Duration"],[52,66,"Parameter"],[68,83,"Parameter"],[89,105,"Parameter"],[113,123,"Parameter"]],"Comments":[]}
{"id":1598,"text":"IC Dose response profiles of reversible and TDI of CYP2C9 enzyme by Labisia pumila root extract (A) and its alkyl phenolic constituents (B–E).","label":[[29,64,"Parameter"],[68,95,"Herb name"],[83,87,"Herb part"],[108,135,"Herb name"]],"Comments":[]}
{"id":1599,"text":"The data are represented as mean ± SD of 3 independent experiments (n = 2 in each experiment).","label":[],"Comments":[]}
{"id":1600,"text":"Dose response profiles of reversible and TDI of CYP2C19 enzyme by Labisia pumila root extract (A) and its alkyl phenolic constituents (B–E).","label":[[26,62,"Parameter"],[66,93,"Herb name"],[81,85,"Herb part"],[106,133,"Herb name"]],"Comments":[]}
{"id":1601,"text":"The data are represented as mean ± SD of 3 independent experiments (n = 2 in each experiment).","label":[],"Comments":[]}
{"id":1602,"text":"IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006).","label":[[41,45,"Target"],[49,94,"Herb name"],[131,141,"Herb name"],[146,153,"Drug"]],"Comments":[]}
{"id":1603,"text":"Calcein-AM uptake was quantified in MDCK and hMDR1-MDCKII cells.","label":[[0,10,"Herb name"],[0,17,"Parameter"]],"Comments":[]}
{"id":1604,"text":"The alkyl phenol compounds showed no increase in the uptake of calcein-AM in hMDR1-MDCKII cells.","label":[[0,26,"Herb name"],[49,73,"Parameter"],[63,73,"Herb name"]],"Comments":[]}
{"id":1605,"text":"The methanolic extract and the two saponins, primulanin, and ardisimamilloside H, increased the uptake of calcein-AM dose dependently with EC Dose-response curves of P-gp inhibition by methanol extract of Labisia pumila roots (A), its two saponin constituents (B–C) and positive control verapamil (D), determined by calculating the percent uptake of calcein AM into hMDR1-MDCKII cells.","label":[[0,22,"Extraction process"],[28,80,"Herb name"],[92,121,"Parameter"],[106,116,"Herb name"],[166,170,"Target"],[185,201,"Extraction process"],[205,219,"Herb name"],[220,225,"Herb part"],[239,259,"Herb name"],[287,296,"Drug"],[328,360,"Parameter"],[350,360,"Herb name"]],"Comments":[]}
{"id":1606,"text":"Equations used in evaluating EC The second probe used to determine the P-gp inhibition was radiolabelled digoxin [ Dose-response curves of P-gp inhibition by methanol extract (A) of Labisia pumila roots, its two saponin constituents (B–C) and positive control cyclosporin A (D), determined by calculating the basolateral to apical transport (%) of  Finally, we looked at the modulation of PXR activity by the extract and the constituents using a reporter gene assay in HepG2 cells.","label":[[71,75,"Target"],[105,112,"Drug"],[139,143,"Target"],[158,174,"Extraction process"],[182,196,"Herb name"],[197,202,"Herb part"],[212,232,"Herb name"],[260,273,"Drug"],[305,344,"Parameter"],[389,401,"Parameter"],[405,437,"Herb name"]],"Comments":[]}
{"id":1607,"text":"One of the alky phenols, fatimahol, significantly induced PXR activity (1.8-fold) at the highest tested concentration of 30 μM, while at lower concentration the effect was not significant Figure 7A.","label":[[0,34,"Herb name"],[58,61,"Target"],[58,70,"Parameter"],[72,80,"Amount"],[104,117,"Parameter"],[121,126,"Amount"],[143,156,"Parameter"]],"Comments":[]}
{"id":1608,"text":"These results suggest that there is no effect on the PXR activation by KF extract or its constituents.","label":[[49,67,"Parameter"],[71,101,"Herb name"]],"Comments":[]}
{"id":1609,"text":"The positive control, rifampicin (10 μM) caused a fourfold induction in PXR activity which is in agreement with previous reports (Li and Chiang, 2006; Figure 7A).","label":[[22,32,"Drug"],[34,39,"Amount"],[72,75,"Target"],[72,84,"Parameter"]],"Comments":[]}
{"id":1610,"text":"On the other hand, the methanolic extract (3–30 μg\/mL) and the two saponins (primulanin and ardisimamilloside H; 3–30 μM) dose dependently decreased rifampicin-induced PXR activity (Figure 7B).","label":[[19,41,"Extraction process"],[43,53,"Amount"],[59,109,"Herb name"],[113,120,"Amount"],[149,159,"Drug"],[149,180,"Parameter"],[168,171,"Target"]],"Comments":[]}
{"id":1611,"text":"These results indicate that L. pumila and its constituents significantly modulate the activity of PXR and thereby could affect the downstream genes involved in PXR signaling.","label":[[28,58,"Herb name"],[82,101,"Parameter"],[160,173,"Parameter"]],"Comments":[]}
{"id":1612,"text":"Additionally, no cytotoxicity was observed toward HepG2 cells with either KF methanolic extract or its constituents up to the highest tested concentration of 30 μg\/mL or 30 μM (data not shown) confirming that the inhibition of PXR as seen with methanolic extract and the two saponins is not due to the toxicity toward HepG2 cells.","label":[[17,29,"Pathology"],[74,115,"Herb name"],[77,95,"Extraction process"],[141,154,"Parameter"],[158,166,"Amount"],[170,175,"Amount"],[227,230,"Target"],[244,262,"Extraction process"],[267,283,"Herb name"],[302,310,"Pathology"]],"Comments":[]}
{"id":1613,"text":"Induction of PXR by fatimahol and rifampicin (A) and inhibition of rifampicin mediated induction of PXR by Labisia pumila methanol extract and its constituents (B) at indicated concentrations.","label":[[13,16,"Target"],[20,29,"Herb name"],[34,44,"Drug"],[67,77,"Drug"],[67,103,"Parameter"],[100,103,"Target"],[107,159,"Herb name"],[122,138,"Extraction process"],[177,191,"Parameter"]],"Comments":[]}
{"id":1614,"text":"Ketoconazole (KTZ) was used as a positive control in the inhibition assay.","label":[[0,18,"Drug"]],"Comments":[]}
{"id":1615,"text":"*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett’s multiple comparison tests.","label":[],"Comments":[]}
{"id":1616,"text":"The data are represented as mean ± SD of triplicate measurements in three independent experiments.","label":[],"Comments":[]}
{"id":1617,"text":"The calculated % yield and concentration per dose (560 mg, single dose) was more for alkyl phenols compared to saponins from KF roots as shown in Table 2.","label":[[27,49,"Parameter"],[51,57,"Amount"],[59,70,"Frequency"],[85,98,"Herb name"],[111,133,"Herb name"],[128,133,"Herb part"]],"Comments":[]}
{"id":1618,"text":"Since the intestinal absorption or plasma concentrations are not known for the test compounds, we made an assumption that all of the compounds are completely absorbed (100% bioavailable) from the GI tract.","label":[[6,31,"Parameter"],[35,56,"Parameter"],[168,172,"Amount"],[173,185,"Parameter"]],"Comments":[]}
{"id":1619,"text":"Based on this, the predicted GI and plasma concentrations of the compounds were calculated as shown in Tables 2 and 3.","label":[[15,74,"Parameter"]],"Comments":[]}
{"id":1620,"text":"The IC Calculation of estimated extract per dose, GIT and plasma concentrations of KF methanol extract and its constituents.","label":[[50,79,"Parameter"],[83,123,"Herb name"],[86,102,"Extraction process"]],"Comments":[]}
{"id":1621,"text":"Prediction of KF methanol extract and its constituents to cause herb drug interaction in vivo based on in vitro data.","label":[[14,54,"Herb name"],[16,33,"Extraction process"]],"Comments":[]}
{"id":1622,"text":"There is increasing evidence that the global use of herbal supplements for the treatment of a wide spectrum of ailments has been on the rise.","label":[[111,119,"Pathology"]],"Comments":[]}
{"id":1623,"text":"Concurrently, there are more clinical cases of toxicity caused by concomitant administration of herbal supplements with conventional medicines (Colalto, 2010).","label":[[47,55,"Pathology"]],"Comments":[]}
{"id":1624,"text":"This risk is mainly attributed due to the lack of research on the drug interaction potential of herbal medicines and their constituents.","label":[[96,135,"Herb name"]],"Comments":[]}
{"id":1625,"text":"Such studies are needed to identify the potential herbs which may cause drug interactions and may help in reducing the risk of clinical toxicity (Chen et al., 2012).","label":[[127,144,"Pathology"]],"Comments":[]}
{"id":1626,"text":"Furthermore, it is also of significant value to identify the constituents responsible for causing drug interactions.","label":[],"Comments":[]}
{"id":1627,"text":"This will also enable us to identify the potential herbs which have similar chemical composition that may cause drug interactions.","label":[],"Comments":[]}
{"id":1628,"text":"Based on the FDA guidelines related to the drug interaction, identifying compounds which interact with drug metabolizing enzymes and eﬄux transporters are of paramount importance since they play a major role in altering the pharmacokinetics and pharmacodynamics of majority of conventional drugs (Huang et al., 2008).","label":[[103,128,"Parameter"],[133,150,"Parameter"]],"Comments":[]}
{"id":1629,"text":"Accordingly, the current study is focused on studying a widely used herb KF and some of its chemical constituents for the possibility of herb-drug interaction mediated by modulating the activities of CYPs, P-gp, and PXR using in vitro methods.","label":[[73,75,"Herb name"],[182,219,"Parameter"]],"Comments":[]}
{"id":1630,"text":"In the present study, the methanolic extract of KF and its constituents showed a moderate inhibition of CYP2D6 and 1A2 at higher concentrations.","label":[[22,44,"Extraction process"],[48,71,"Herb name"],[104,118,"Target"],[129,143,"Parameter"]],"Comments":[]}
{"id":1631,"text":"It is unlikely that most of these compounds will accumulate to such high physiological concentrations after oral intake.","label":[[73,101,"Parameter"]],"Comments":[]}
{"id":1632,"text":"However, saponins isolated from Panax notoginseng were found to induce CYP1A2 with no inhibitory effect on the activity of other CYPs (Liu et al., 2012).","label":[[9,49,"Herb name"],[71,77,"Target"],[107,133,"Parameter"]],"Comments":[]}
{"id":1633,"text":"In contrast, we observed a strong inhibition of CYP3A4, 2C19, and 2C9 by saponins and methanol extract of KF.","label":[[48,69,"Target"],[73,108,"Herb name"],[86,102,"Extraction process"]],"Comments":[]}
{"id":1634,"text":"In a previous study, crude extracts of KF have been reported to inhibit CYP2C isoforms; however, minimal effect was seen on CYP3A4 enzyme (Pan et al., 2012).","label":[[21,41,"Extraction process"],[39,41,"Herb name"],[72,86,"Target"],[124,137,"Parameter"]],"Comments":[]}
{"id":1635,"text":"These differences toward CYP3A4 activity may be attributed to the differences in the chemical composition of the extracts used in separate studies.","label":[[25,40,"Parameter"]],"Comments":[]}
{"id":1636,"text":"Time dependent inhibitors are categorized as mechanism based inhibitors.","label":[],"Comments":[]}
{"id":1637,"text":"Such inhibitors are generally considered to have more profound clinical effects compared to reversible inhibitors as they form strong covalent bonds and thereby inactivate the CYPs (Riley et al., 2007; Venkatakrishnan et al., 2007).","label":[[172,180,"Parameter"]],"Comments":[]}
{"id":1638,"text":"In order to find out if the methanolic extract or the constituents cause any TDI, the shift in IC P-gp is known to contain multiple binding sites and consequently multiple probe substrates are recommended to determine if a compound is an inhibitor (Martin et al., 2000).","label":[[24,46,"Extraction process"],[98,102,"Parameter"],[172,188,"Parameter"]],"Comments":[]}
{"id":1639,"text":"We used calcein-AM and digoxin as our probe substrates as they are known to bind two different binding pockets of P-gp (Rautio et al., 2006).","label":[[8,18,"Herb name"],[23,30,"Drug"],[114,118,"Parameter"]],"Comments":[]}
{"id":1640,"text":"In the calcein-AM assay, the two saponins and the extract showed P-gp inhibition to a similar extent as verapamil but significantly lower than cyclosporin A.","label":[[7,17,"Herb name"],[25,57,"Herb name"],[65,69,"Target"],[104,113,"Drug"],[143,156,"Drug"]],"Comments":[]}
{"id":1641,"text":"However, using digoxin as the substrate, much more potent inhibition of P-gp was seen.","label":[[15,22,"Drug"],[72,76,"Target"]],"Comments":[]}
{"id":1642,"text":"A similar trend was seen with verapamil which showed more potency in the digoxin assay, in accordance to previous report (Rautio et al., 2006).","label":[[30,39,"Drug"],[73,80,"Drug"]],"Comments":[]}
{"id":1643,"text":"Our results indicate that the components of KF exhibit similar mechanism of P-gp inhibition as verapamil.","label":[[44,46,"Herb name"],[76,80,"Target"],[95,104,"Drug"]],"Comments":[]}
{"id":1644,"text":"Compounds which show IC In conclusion, this study demonstrated that the methanolic extract of KF and its constituents strongly inhibited (TDI) a major drug metabolizing enzyme CYP3A4, while a moderate reversible inhibition was seen with CYP2C9 and 2C19 with minimal effects on CYP 2D6 and 1A2.","label":[[68,117,"Extraction process"],[94,96,"Herb name"],[143,182,"Target"],[237,252,"Target"],[277,292,"Target"]],"Comments":[]}
{"id":1645,"text":"Inhibition of P-gp and PXR by the methanol extract could be attributed to the presence of saponins while inhibition of CYPs could be due to alkyl phenols.","label":[[14,26,"Target"],[30,50,"Extraction process"],[90,98,"Herb name"],[119,123,"Target"],[140,153,"Herb name"]],"Comments":[]}
{"id":1646,"text":"Taken together, concomitant use of L. pumila (KF) with conventional drugs could cause a possibility of drug-herb interaction.","label":[[35,49,"Herb name"],[55,73,"Drug"]],"Comments":[]}
{"id":1647,"text":"Further studies are warranted in this direction.","label":[],"Comments":[]}
{"id":1648,"text":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","label":[],"Comments":[]}
{"id":1649,"text":"The United States Department of Agriculture, Agricultural Research Service, Specific Cooperative Agreement No.","label":[],"Comments":[]}
{"id":1650,"text":"58-6408-1-603 and the United States Food and Drug Administration (FDA; Grant No.","label":[],"Comments":[]}
{"id":1651,"text":"1U01FD004246-3) are acknowledged for partial support of this work.","label":[],"Comments":[]}
{"id":1652,"text":"The opinions expressed herein are attributable to the authors only, and do not represent the position of the FDA or any government agency.","label":[],"Comments":[]}
{"id":1653,"text":"Holista Biotech Sdn Bhd, Malaysia, is also acknowledged for partial support and providing the authenticated plant material but Holista did not contribute to this report, nor does the work represent their opinions.","label":[],"Comments":[]}
{"id":1654,"text":"Cytochrome P450 enzymes Food and Drug Administration human hepatocellular carcinoma human multidrug resistance-1-transfected Madin-Darby canine kidney Madin-Darby canine kidney Lucifer yellow P-glycoprotein Pregnane X receptor Time dependent inhibition.","label":[[0,23,"Parameter"],[74,83,"Pathology"],[192,206,"Parameter"],[207,226,"Parameter"]],"Comments":[]}
